C-N Huang1, S-P Huang2, J-B Pao3, T-Y Chang4, Y-H Lan5, T-L Lu5, H-Z Lee5, S-H Juang6, P-P Wu5, Y-S Pu7, C-J Hsieh8, B-Y Bao9. 1. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung. 2. Department of Urology, Kaohsiung Medical University Hospital, Kaohsiung; Department of Urology, Kaohsiung Municipal Hsiao-Kang Hospital, Kaohsiung; Department of Urology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung. 3. Department of Pharmacy Practice, Tri-Service General Hospital, Taipei. 4. Departments of Occupational Safety and Health. 5. Departments of Pharmacy, China Medical University, Taichung. 6. Departments of Graduate Institute of Pharmaceutical Chemistry, China Medical University, Taichung. 7. Department of Urology, National Taiwan University Hospital, Taipei. 8. Department of Health Care Administration, Oriental Institute of Technology, Taipei; Graduate Institute of Health Care Organization Administration, College of Public Health, National Taiwan University, Taipei. 9. Departments of Pharmacy, China Medical University, Taichung; Sex Hormone Research Center, China Medical University Hospital, Taichung, Taiwan. Electronic address: bao@mail.cmu.edu.tw.
Abstract
BACKGROUND: Activated androgen receptor binds to androgen-responsive elements (AREs) in genome to regulate target gene transcription and, consequently, mediates physiological or tumorigenic processes of the prostate. Our aim was to determine whether genetic variants in AREs are associated with clinical outcomes after androgen-deprivation therapy (ADT) in prostate cancer patients. PATIENTS AND METHODS: We systematically investigated 55 common single-nucleotide polymorphisms (SNPs) in the genome-wide insilico-predicted AREs in a cohort of 601 men with advanced prostate cancer treated with ADT. The prognostic significance of these SNPs on disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT was assessed by Kaplan-Meier analysis and Cox regression model. RESULTS: In univariate analysis, two, five, and four SNPs were associated with disease progression, PCSM, and ACM, respectively. After adjusting for known prognostic factors, ARRDC3 rs2939244, FLT1 rs9508016, and SKAP1 rs6504145 remained as significant predictors for PCSM and FBXO32 rs7830622 and FLT1 rs9508016 remained as significant predictors for ACM in multivariate analysis. Moreover, strong combined genotype effects on PCSM and ACM were also observed (P(trend) < 0.001). CONCLUSION: Our results suggest that SNPs in AREs influence prostate cancer survival and may further advance our understanding of the disease progression.
BACKGROUND: Activated androgen receptor binds to androgen-responsive elements (AREs) in genome to regulate target gene transcription and, consequently, mediates physiological or tumorigenic processes of the prostate. Our aim was to determine whether genetic variants in AREs are associated with clinical outcomes after androgen-deprivation therapy (ADT) in prostate cancerpatients. PATIENTS AND METHODS: We systematically investigated 55 common single-nucleotide polymorphisms (SNPs) in the genome-wide insilico-predicted AREs in a cohort of 601 men with advanced prostate cancer treated with ADT. The prognostic significance of these SNPs on disease progression, prostate cancer-specific mortality (PCSM) and all-cause mortality (ACM) after ADT was assessed by Kaplan-Meier analysis and Cox regression model. RESULTS: In univariate analysis, two, five, and four SNPs were associated with disease progression, PCSM, and ACM, respectively. After adjusting for known prognostic factors, ARRDC3rs2939244, FLT1rs9508016, and SKAP1rs6504145 remained as significant predictors for PCSM and FBXO32rs7830622 and FLT1rs9508016 remained as significant predictors for ACM in multivariate analysis. Moreover, strong combined genotype effects on PCSM and ACM were also observed (P(trend) < 0.001). CONCLUSION: Our results suggest that SNPs in AREs influence prostate cancer survival and may further advance our understanding of the disease progression.
Authors: Richard Marcotte; Kevin R Brown; Fernando Suarez; Azin Sayad; Konstantina Karamboulas; Paul M Krzyzanowski; Fabrice Sircoulomb; Mauricio Medrano; Yaroslav Fedyshyn; Judice L Y Koh; Dewald van Dyk; Bodhana Fedyshyn; Marianna Luhova; Glauber C Brito; Franco J Vizeacoumar; Frederick S Vizeacoumar; Alessandro Datti; Dahlia Kasimer; Alla Buzina; Patricia Mero; Christine Misquitta; Josee Normand; Maliha Haider; Troy Ketela; Jeffrey L Wrana; Robert Rottapel; Benjamin G Neel; Jason Moffat Journal: Cancer Discov Date: 2011-12-29 Impact factor: 39.397
Authors: Virpi H Laitinen; Tommi Rantapero; Daniel Fischer; Elisa M Vuorinen; Teuvo L J Tammela; Tiina Wahlfors; Johanna Schleutker Journal: Int J Cancer Date: 2014-11-08 Impact factor: 7.396
Authors: Sajjad Rafiq; William Tapper; Andrew Collins; Sofia Khan; Ioannis Politopoulos; Sue Gerty; Carl Blomqvist; Fergus J Couch; Heli Nevanlinna; Jianjun Liu; Diana Eccles Journal: Cancer Res Date: 2013-01-14 Impact factor: 12.701